by Sermonix Pharmaceuticals | Dec 12, 2023 | News
Most patients minimized or hid side effects from their health care providers for fear of negative perceptions, reduced treatment efficacy, or being taken off a drug or out of a clinical trial Sexual dysfunction was the most commonly cited side effect with a negative...
by Sermonix Pharmaceuticals | Dec 12, 2023 | News
COLUMBUS, Ohio, Dec. 12, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today broadly shared the...
by Sermonix Pharmaceuticals | Dec 11, 2023 | News
COLUMBUS, Ohio, Dec. 11, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that results...
Recent Comments